ATYR Stock Price | aTyr Pharma, Inc. P/E, Revenue, EPS, & Forecasts

aTyr Pharma, Inc. • ATYR

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About aTyr Pharma, Inc.

Ticker

ATYR

Trading on

NASDAQ

ISIN

US0021202025

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Sanjay S. Shukla M.D., M.S.

Headquarters

10240 Sorrento Valley Road, San Diego, CA, United States, 92121

Employees

Website

atyrpharma.com

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Metrics

BasicAdvanced

Market cap

$144M

P/E ratio

EPS

-$0.90

Dividend Yield

0.00%

Beta

1.21

Forward P/E ratio

EBIDTA

$-61.8M

Ex dividend date

Price & volume

Market cap

$144M

Average daily volume

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

244.92

Price to book

1.76

Earnings

EPS

-$0.90

EPS estimate (current quarter)

$0.00

EPS estimate (next quarter)

$0.00

EBITDA

$-61.8M

Revenues (TTM)

$0.6M

Revenues per share (TTM)

$0.01

Technicals

Beta

1.21

52-week High

$4.66

52-week Low

$1.42

50-day moving average

$1.84

200-day moving average

$1.71

Short ratio

1.47

Short %

0.79%

Management effectiveness

ROE (TTM)

61.76%

ROA (TTM)

32.74%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

10,633.50%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

75.8M

Float

73.8M

Insiders %

2.39%

Institutions %

64.48%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 8 analysts.

Average price target

$22.00

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.20

-$0.23

13.04%

Q3 • 23Beat

-$0.25

-$0.24

4.17%

Q4 • 23Beat

-$0.23

-$0.24

4.17%

Q1 • 24Beat

-$0.23

-$0.24

6.00%

Q2 • 24Beat

-$0.23

-$0.22

3.50%

Q3 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-17.3M

∞%

Q3 • 24

$0M

$-15M

∞%

Q4 • 24

NaN%

13.28%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$91.6M

$26.5M

28.90%

Q3 • 24

$96.8M

$27M

27.88%

Q4 • 24

5.69%

1.97%

3.52%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-13.2M

$17.9M

$-0.1M

$-13.2M

Q3 • 24

$-13.1M

$-6.1M

$18.8M

$-13.2M

Q4 • 24

0.20%

133.91%

18,041.90%

0.12%

QoQ growth

QuarterlyAnnual

Sentiment analysis

-1.5

Greed

+1.5

0.38

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a aTyr Pharma, Inc. share?

aTyr Pharma, Inc. shares are currently traded for undefined per share.

How many shares does aTyr Pharma, Inc. have?

aTyr Pharma, Inc. currently has 75.8M shares.

Does aTyr Pharma, Inc. pay dividends?

No, aTyr Pharma, Inc. doesn't pay dividends.

What is aTyr Pharma, Inc. 52 week high?

aTyr Pharma, Inc. 52 week high is $4.66.

What is aTyr Pharma, Inc. 52 week low?

aTyr Pharma, Inc. 52 week low is $1.42.

What is the 200-day moving average of aTyr Pharma, Inc.?

aTyr Pharma, Inc. 200-day moving average is $1.71.

Who is aTyr Pharma, Inc. CEO?

The CEO of aTyr Pharma, Inc. is Dr. Sanjay S. Shukla M.D., M.S..

How many employees aTyr Pharma, Inc. has?

aTyr Pharma, Inc. has 0 employees.

What is the market cap of aTyr Pharma, Inc.?

The market cap of aTyr Pharma, Inc. is $144M.

What is the P/E of aTyr Pharma, Inc.?

The current P/E of aTyr Pharma, Inc. is null.

What is the EPS of aTyr Pharma, Inc.?

The EPS of aTyr Pharma, Inc. is -$0.90.

What is the PEG Ratio of aTyr Pharma, Inc.?

The PEG Ratio of aTyr Pharma, Inc. is null.

What do analysts say about aTyr Pharma, Inc.?

According to the analysts aTyr Pharma, Inc. is considered a buy.